Cargando…

Cost-Effectiveness Analysis of Insulin Detemir Compared to Neutral Protamine Hagedorn (NPH) in Patients with Type 1 and Type 2 Diabetes Mellitus in Spain

INTRODUCTION: An Excel(®) (Microsoft Corporation) model was adapted to estimate the short-term (1-year) cost effectiveness of insulin detemir (IDet) versus neutral protamine Hagedorn (NPH) insulin in patients initiating insulin treatment with type 1 diabetes mellitus (T1DM) and type 2 diabetes melli...

Descripción completa

Detalles Bibliográficos
Autores principales: Morales, Cristóbal, de Luis, Daniel, de Arellano, Antonio Ramírez, Ferrario, Maria Giovanna, Lizán, Luis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4674462/
https://www.ncbi.nlm.nih.gov/pubmed/26589521
http://dx.doi.org/10.1007/s13300-015-0143-x
_version_ 1782404897400946688
author Morales, Cristóbal
de Luis, Daniel
de Arellano, Antonio Ramírez
Ferrario, Maria Giovanna
Lizán, Luis
author_facet Morales, Cristóbal
de Luis, Daniel
de Arellano, Antonio Ramírez
Ferrario, Maria Giovanna
Lizán, Luis
author_sort Morales, Cristóbal
collection PubMed
description INTRODUCTION: An Excel(®) (Microsoft Corporation) model was adapted to estimate the short-term (1-year) cost effectiveness of insulin detemir (IDet) versus neutral protamine Hagedorn (NPH) insulin in patients initiating insulin treatment with type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) in Spain. METHODS: Clinical benefits included the non-severe hypoglycemia rate for T1DM and T2DM, and weight change for T2DM. Three scenarios were included with different hypoglycemia rates estimated on the basis of clinical trials and observational studies. Costs, estimated from perspective of the Spanish Public Healthcare System (Euros 2014), included insulin treatment and non-severe hypoglycemia management costs. Non-severe hypoglycemia, defined as a self-managed event, implied the use of extra glucose testing strips and a general practitioner visit during the week following the event for 25% of patients. An average disutility value was associated to non-severe hypoglycemia events and, for T2DM, to one body mass index unit gain to calculate quality-adjusted life years (QALYs). RESULTS: For the three scenarios a range of 0.025–0.076 QALYs for T1DM and 0.014–0.051 QALYs for T2DM were gained for IDet versus NPH due to non-severe hypoglycemia and weight gain avoidance, in return of an incremental cost of €145–192 for T1DM and €128–206 for T2DM. This resulted in the IDet versus NPH incremental cost-effectiveness ratio (ICER) ranging between €1910/QALY and €7682/QALY for T1DM and €2522/QALY and €15,009/QALY for T2DM. CONCLUSION: IDet was a cost-effective alternative to NPH insulin in the first year of treatment of patients with T1DM and patients with T2DM in Spain, with ICERs under the threshold value commonly accepted in Spain (€30,000/QALY). FUNDING: Novo Nordisk. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s13300-015-0143-x) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4674462
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-46744622015-12-17 Cost-Effectiveness Analysis of Insulin Detemir Compared to Neutral Protamine Hagedorn (NPH) in Patients with Type 1 and Type 2 Diabetes Mellitus in Spain Morales, Cristóbal de Luis, Daniel de Arellano, Antonio Ramírez Ferrario, Maria Giovanna Lizán, Luis Diabetes Ther Original Research INTRODUCTION: An Excel(®) (Microsoft Corporation) model was adapted to estimate the short-term (1-year) cost effectiveness of insulin detemir (IDet) versus neutral protamine Hagedorn (NPH) insulin in patients initiating insulin treatment with type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) in Spain. METHODS: Clinical benefits included the non-severe hypoglycemia rate for T1DM and T2DM, and weight change for T2DM. Three scenarios were included with different hypoglycemia rates estimated on the basis of clinical trials and observational studies. Costs, estimated from perspective of the Spanish Public Healthcare System (Euros 2014), included insulin treatment and non-severe hypoglycemia management costs. Non-severe hypoglycemia, defined as a self-managed event, implied the use of extra glucose testing strips and a general practitioner visit during the week following the event for 25% of patients. An average disutility value was associated to non-severe hypoglycemia events and, for T2DM, to one body mass index unit gain to calculate quality-adjusted life years (QALYs). RESULTS: For the three scenarios a range of 0.025–0.076 QALYs for T1DM and 0.014–0.051 QALYs for T2DM were gained for IDet versus NPH due to non-severe hypoglycemia and weight gain avoidance, in return of an incremental cost of €145–192 for T1DM and €128–206 for T2DM. This resulted in the IDet versus NPH incremental cost-effectiveness ratio (ICER) ranging between €1910/QALY and €7682/QALY for T1DM and €2522/QALY and €15,009/QALY for T2DM. CONCLUSION: IDet was a cost-effective alternative to NPH insulin in the first year of treatment of patients with T1DM and patients with T2DM in Spain, with ICERs under the threshold value commonly accepted in Spain (€30,000/QALY). FUNDING: Novo Nordisk. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s13300-015-0143-x) contains supplementary material, which is available to authorized users. Springer Healthcare 2015-11-20 2015-12 /pmc/articles/PMC4674462/ /pubmed/26589521 http://dx.doi.org/10.1007/s13300-015-0143-x Text en © The Author(s) 2015 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Research
Morales, Cristóbal
de Luis, Daniel
de Arellano, Antonio Ramírez
Ferrario, Maria Giovanna
Lizán, Luis
Cost-Effectiveness Analysis of Insulin Detemir Compared to Neutral Protamine Hagedorn (NPH) in Patients with Type 1 and Type 2 Diabetes Mellitus in Spain
title Cost-Effectiveness Analysis of Insulin Detemir Compared to Neutral Protamine Hagedorn (NPH) in Patients with Type 1 and Type 2 Diabetes Mellitus in Spain
title_full Cost-Effectiveness Analysis of Insulin Detemir Compared to Neutral Protamine Hagedorn (NPH) in Patients with Type 1 and Type 2 Diabetes Mellitus in Spain
title_fullStr Cost-Effectiveness Analysis of Insulin Detemir Compared to Neutral Protamine Hagedorn (NPH) in Patients with Type 1 and Type 2 Diabetes Mellitus in Spain
title_full_unstemmed Cost-Effectiveness Analysis of Insulin Detemir Compared to Neutral Protamine Hagedorn (NPH) in Patients with Type 1 and Type 2 Diabetes Mellitus in Spain
title_short Cost-Effectiveness Analysis of Insulin Detemir Compared to Neutral Protamine Hagedorn (NPH) in Patients with Type 1 and Type 2 Diabetes Mellitus in Spain
title_sort cost-effectiveness analysis of insulin detemir compared to neutral protamine hagedorn (nph) in patients with type 1 and type 2 diabetes mellitus in spain
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4674462/
https://www.ncbi.nlm.nih.gov/pubmed/26589521
http://dx.doi.org/10.1007/s13300-015-0143-x
work_keys_str_mv AT moralescristobal costeffectivenessanalysisofinsulindetemircomparedtoneutralprotaminehagedornnphinpatientswithtype1andtype2diabetesmellitusinspain
AT deluisdaniel costeffectivenessanalysisofinsulindetemircomparedtoneutralprotaminehagedornnphinpatientswithtype1andtype2diabetesmellitusinspain
AT dearellanoantonioramirez costeffectivenessanalysisofinsulindetemircomparedtoneutralprotaminehagedornnphinpatientswithtype1andtype2diabetesmellitusinspain
AT ferrariomariagiovanna costeffectivenessanalysisofinsulindetemircomparedtoneutralprotaminehagedornnphinpatientswithtype1andtype2diabetesmellitusinspain
AT lizanluis costeffectivenessanalysisofinsulindetemircomparedtoneutralprotaminehagedornnphinpatientswithtype1andtype2diabetesmellitusinspain